Ceva Santé Animale was the fastest growing Top 10 veterinary health company through our first 10 years of existence* . We now rank as the ninth largest animal health group globally – and we were only founded in 1999! Our expertise centres on the two fields of pharmacology and biology, where we have dedicated teams that aim to meet the specific demands of the companion animal, poultry, ruminant and swine sectors. We continually strive to find better solutions to existing and emerging diseases which will in turn improve animal health and productivity.
Our care extends beyond animal health and welfare. These days, a staggering 75% of all emerging human infectious diseases are of animal origin. Ceva is involved in the fight against the spread of infectious disease that can be transmitted from wild or domestic animals and birds to humans – diseases known as zoonoses, which include avian flu, brucellosis and Q-fever.
Ceva is a visible supporter of and contributor to various welfare and social programmes all over the world. Our work ranges from researching, developing, producing and supplying animal health products to the poorest livestock owners in the world, of which our SOS (Stamp Out Sleeping sickness) programme in Uganda is a good example; to supplying the UK’s largest dog welfare charity with Dog Appeasing Pheromone (DAP) collars, to help make the lives of dogs in shelter less stressful.
Ceva successfully combines profitability with long-term growth.
Our global business operations are divided into six major zones : Western Europe, Central and Eastern Europe (incl. Turkey), North America, Latin America, Africa/Middle East and Asia/Pacific.
We are directly present in 40 countries, have 11 research and development centres, 17 production sites and 2 543 employees worldwide. The company is focused on the research, development, production and marketing of pharmaceutical products and vaccines for companion animal, poultry, ruminant and swine.
*Source: Vetnosis, CAGR period 1999-2009